Literature DB >> 27411816

Metformin inhibits development of colon malignant tumors induced by 1,2-dimethylhydrazine in rats.

V V Bekusova1, V M Patsanovskii2, A D Nozdrachev3, V N Anisimov4.   

Abstract

It has been shown that metformin dose-dependently inhibits the development of colon tumors induced by 1,2-dimethylhydrazine (DMH) in rats. The metformin effect manifested itself as a decrease in the amount and average size of tumors, increased degree of their differentiation, and reduction of invasion depth, which was more pronounced in the group of animals that received metformin at a dose of 100 mg/kg of body weight as compared with rats treated with metformin at a dose of 300 mg/kg.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27411816     DOI: 10.1134/S0012496616030017

Source DB:  PubMed          Journal:  Dokl Biol Sci        ISSN: 0012-4966


  13 in total

1.  Cancer research. Unraveling the obesity-cancer connection.

Authors:  Gary Taubes
Journal:  Science       Date:  2012-01-06       Impact factor: 47.728

Review 2.  The key role of growth hormone-insulin-IGF-1 signaling in aging and cancer.

Authors:  Vladimir N Anisimov; Andrzej Bartke
Journal:  Crit Rev Oncol Hematol       Date:  2013-02-21       Impact factor: 6.312

Review 3.  Experimental intestinal cancer research with special reference to human pathology.

Authors:  K M Pozharisski; A J Likhachev; V F Klimashevski; J D Shaposhnikov
Journal:  Adv Cancer Res       Date:  1979       Impact factor: 6.242

Review 4.  Statistical methods in cancer research. Volume III--The design and analysis of long-term animal experiments.

Authors:  J J Gart; D Krewski; P N Lee; R E Tarone; J Wahrendorf
Journal:  IARC Sci Publ       Date:  1986

Review 5.  Do metformin a real anticarcinogen? A critical reappraisal of experimental data.

Authors:  Vladimir N Anisimov
Journal:  Ann Transl Med       Date:  2014-06

6.  Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase.

Authors:  Kunihiro Hosono; Hiroki Endo; Hirokazu Takahashi; Michiko Sugiyama; Takashi Uchiyama; Kaori Suzuki; Yuichi Nozaki; Kyoko Yoneda; Koji Fujita; Masato Yoneda; Masahiko Inamori; Akiko Tomatsu; Takeshi Chihara; Kan Shimpo; Hitoshi Nakagama; Atsushi Nakajima
Journal:  Mol Carcinog       Date:  2010-07       Impact factor: 4.784

7.  Cancer statistics, 2012.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2012-01-04       Impact factor: 508.702

Review 8.  Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena.

Authors:  Begoña Martin-Castillo; Alejandro Vazquez-Martin; Cristina Oliveras-Ferraros; Javier A Menendez
Journal:  Cell Cycle       Date:  2010-03-15       Impact factor: 4.534

Review 9.  Modern approach to metabolic rehabilitation of cancer patients: biguanides (phenformin and metformin) and beyond.

Authors:  Lev M Berstein
Journal:  Future Oncol       Date:  2010-08       Impact factor: 3.404

10.  Role of metformin in suppressing 1,2-dimethylhydrazine-induced colon cancer in diabetic and non-diabetic mice: effect on tumor angiogenesis and cell proliferation.

Authors:  Dalia K Zaafar; Sawsan A Zaitone; Yasser M Moustafa
Journal:  PLoS One       Date:  2014-06-27       Impact factor: 3.240

View more
  2 in total

Review 1.  Metformin and Colorectal Cancer.

Authors:  Takuma Higurashi; Atsushi Nakajima
Journal:  Front Endocrinol (Lausanne)       Date:  2018-10-23       Impact factor: 5.555

2.  Metformin for cancer and aging prevention: is it a time to make the long story short?

Authors:  Vladimir N Anisimov
Journal:  Oncotarget       Date:  2015-11-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.